Improving Liver Disease Diagnosis in the Emergency Department
This study, called STIRRED, aims to improve how a common liver condition called hepatic steatosis (fatty liver) is identified and managed in the emergency department (ED). Often, fatty liver is found on imaging but not fully addressed. The study uses a special computer system (STIRRED intervention) that alerts ED doctors to fatty liver findings when you're being discharged. This system also helps doctors understand your risk and recommends follow-up care. We want to see if this system helps more high-risk patients get a diagnosis related to fatty liver disease within 120 days after leaving the ED. You might be able to join if you are 18 or older, have fatty liver found on an ED imaging study, are discharged home from the ED, and this is your first ED visit at Northwestern Medicine during the study period with this finding. You cannot join if you are admitted to the hospital, under 18, or already have certain liver diseases.
- Study design
- This is an interventional study with a planned enrollment of 4704 participants. It tests a behavioral intervention for ED clinicians.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will track if you receive a new liver disease-related diagnosis within 120 days after being discharged from the ED.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Improving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED
At a glance
Conditions
NCT06944353
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Northwestern Memorial Hospital
Chicago, Illinoisno site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Amy V Kontrick, MD · PRINCIPAL_INVESTIGATOR · Northwestern University
- Danielle M McCarthy, MD · PRINCIPAL_INVESTIGATOR · Northwestern University
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Effectiveness: New steatotic liver disease-related diagnosis among high-risk patients120 days post-ED discharge
For patients at high risk for liver fibrosis, The investigators will evaluate for new steatotic liver disease related ICD codes.
- Implementation: Intervention fidelityBaseline at time of intervention delivery
Fidelity is the degree to which the STIRRED CDSS was delivered as intended. Fidelity will be evaluated across four components: 1. hepatic steatosis added to the ED discharge diagnoses; 2. hepatic steatosis patient education provided; 3. ED adoption of confirming that the clinicians have informed the patient of the new finding; and 4. ED adoption of placing referral and/or recommendation for follow-up (distinct from routing the message to PCP). The Investigators will analyze individual components and a composite score of 0-4 that combines these outcomes. The fidelity components and their composite score (0-4) will be audited monthly from 3 months prior to implementation to 3 months after implementation.